A feasibility study to assess the role of pharmacists in lung cancer diagnosis compared to current pathways

Submission date 09/07/2020	Recruitment status No longer recruiting	 Prospectively re [X] Protocol 	
Registration date 10/07/2020	Overall study status Completed	[/] Statistical analys	
		[X] Results	
Last Edited 13/10/2022	Condition category Cancer	[_] Individual partici	

egistered

sis plan

cipant data

Plain English summary of protocol

Background and study aims

The study aims to find out what people think about using pharmacists to refer people with lung symptoms for a chest x-ray to check for lung cancer. We will see if this could be something that could be used in the future, and what we can do to improve it.

Who can participate?

Members of the public attending pharmacies with some lung symptoms e.g. a cough, who are smokers or ex-smokers.

What does the study involve?

The pharmacist will ask you some questions about your health. If they feel you need a chest x-ray they will send you for one. You will be referred to the hospital for a chest x-ray. The hospital will send you a letter or ring you to let you know your results. You might be asked to go to the hospital for further tests if needed. The pharmacist will give you a short guestionnaire to fill in when you get home. Some people will be invited to take part in an interview and the researcher will be asking questions to get a better idea of what you thought about the service, why you went to your pharmacist for advice and how we can help other people to access this help in the future.

What are the possible benefits and risks of participating?

The results of the research will help us to understand what services can make the most difference to patients. This can help other patients like you in the future. It may also mean that you can get the appropriate treatment for your symptoms.

The symptoms that you have described to your pharmacist mean that a chest x-ray is recommended in guidance from the National Institute for Health and Care Clinical Excellence (NICE). We would recommend you have a chest x-ray even if you chose not to participate in the study. A chest x-ray is a form of ionising radiation that allows images to be made of your body. Exposure to large amounts of ionising radiation can carry risks to the body, for example, it can cause cell damage that may, over many years and decades, turn cancerous. The amount of

radiation that a chest x-ray will expose you to is very small and is the same amount of exposure as 2 days natural radiation from the environment. This has less than 1 in 1 million chance of causing cancer.

Where is the study run from?

There are 16 community pharmacies participating in the study, all based in the Llanelli or Burry Port area of Hywel Dda University Health Board.

When is the study starting and how long is it expected to run for? May 2018 to August 2020

Who is funding the study? Health and Care Research Wales (UK)

Who is the main contact? Dr Rachel Gemine rachel.e.gemine@wales.nhs.uk Mrs Sarah Rees sarah.rees7@wales.nhs.uk

Contact information

Type(s) Public

Contact name Mrs Sarah Rees

Contact details

Beacon Centre for Enterprise Llanelli United Kingdom SA14 6DS +44 (0)1554 899018 sarah.rees7@wales.nhs.uk

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 231842

ClinicalTrials.gov number Nil known

Secondary identifying numbers IRAS 231842

Study information

Scientific Title

Pharmacy referral for Lung cancer Symptoms: a feasibility study to assess the role of pharmacists in lung cancer diagnosis compared to current pathways

Acronym

PLUS1

Study objectives

To monitor numbers of patients suitable for referral/willingness to be referred for chest x-ray by community pharmacies and subsequent lung cancer diagnosis rates.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/11/2018, Wales REC6 (Health and Care Research Wales Support and Delivery Centre, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB; +44 (0)1874 615950; Wales.REC6@wales.nhs.uk) ref: 18/WA/0215

Study design

Observational mixed methods

Primary study design Observational

Secondary study design

Case series

Study setting(s)

Community

Study type(s) Diagnostic

Participant information sheet

Health condition(s) or problem(s) studied Lung cancer

Interventions

Members of the public presenting at community pharmacies with symptoms of lung cancer will be offered a consultation with the pharmacist and if required, direct referral to the local hospital for a chest x-ray. Participants will also be asked to complete a questionnaire and invited to a qualitative interview with a researcher, following their x-ray.

Intervention Type Other

Primary outcome measure

1. Number of patients referred via the pathway measured using case report forms at the end of the study

2. Number of patients referred with a lung cancer diagnosis measured using patient records at the end of the study

Secondary outcome measures

Assessed using a novel questionnaire and interview at a single time point:

- 1. Acceptability of the pathway to patients and healthcare professionals
- 2. Perceived impact on pharmacy workload and radiology referrals
- 3. Patient and professional views and experiences of consulting the pharmacist

Overall study start date

31/05/2018

Completion date

31/08/2020

Eligibility

Key inclusion criteria

1. Individuals over the age of 40, who are current or ex-smokers with a history of 10 or more smoking pack-years, and have had 1 or more of the following, for more than three weeks:

- 1.1. Coughing up blood
- 1.2. High pitched audible wheeze
- 1.3. Neck vein engorgement/facial swelling
- 1.4. Cough
- 1.5. Chest and/or shoulder pain
- 1.6. Unexplained weight loss
- 1.7. Shortness of breath
- 1.8. Hoarse voice
- 1.9. Finger clubbing
- 1.10. Swollen nodes in the head or neck
- 2. Community pharmacists and respiratory physicians involved in patient care

Participant type(s)

Mixed

Age group

Adult

Sex Both

Target number of participants 228

Key exclusion criteria

1. Unable or unwilling to provide written informed consent

2. Patients who have a diagnosed cognitive impairment will be excluded from the evaluation/

follow up element of the study 3. WHO performance status 4

Date of first enrolment 01/05/2019

Date of final enrolment 31/03/2020

Locations

Countries of recruitment United Kingdom

Wales

Study participating centre Prince Philip Hospital Hywel Dda University Health Board Bryngwyn Mawr Dafen Llanelli United Kingdom SA14 8QF

Sponsor information

Organisation Hywel Dda University Health Board

Sponsor details

2nd Floor Sealyham Block Withybush Hospital Haverfordwest Wales United Kingdom SA61 2PZ +44 (0)1437773813 chris.tattersall@wales.nhs.uk

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/012gye839

Funder(s)

Funder type Government

Funder Name Health and Care Research Wales

Alternative Name(s) Health & Care Research Wales, Ymchwil Iechyd a Gofal Cymru, Health Care Research Wales, HCRW

Funding Body Type Government organisation

Funding Body Subtype Local government

Location United Kingdom

Results and Publications

Publication and dissemination plan

The results of the study will be disseminated via peer reviewed scientific journals, internal reports, conference presentations and website publications.

Intention to publish date

31/08/2021

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version V2.1	22/01/2019	07/08/2020	No	Yes
Protocol file	version V2.0	23/08/2018	07/08/2020	No	No
<u>Results article</u>		09/08/2021	11/11/2021	Yes	No
<u>Plain English results</u>			13/10/2022	No	Yes

HRA research summary

28/06/2023 No

No